Results 171 to 180 of about 56,599 (248)

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 6, Page 994-1004, June 2026.
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Bruce Strober, Melinda Gooderham, Wendy Zhang, Junichiro Shimauchi, Masafumi Yaguchi, Takeshi Kimura, Ryuichi Ogawa, Hamid Amouzadeh, Masamoto Murakami   +15 more
wiley   +1 more source

Correction: Comparative efficacy and safety of etanercept and adalimumab in the treatment of polyarticular juvenile idiopathic arthritis. [PDF]

BMC Pediatr
Ge L, Gao Y, Chen X, Guo J, Zhang D, Yang Y.   +5 more
europepmc   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 6, Page 963-979, June 2026.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source

Anti-Inflammatory and Synaptic Protective Effects of TNF-α Inactivation in the MDX Mouse Model. [PDF]

Curr Issues Mol Biol
Bonani AO, Matheus V, Tomiyama ALMR, de Oliveira ALR.   +3 more
europepmc   +1 more source

Is Etanercept A Safe and Effective Treatment For Ankylosing Spondylitis?

, 2012
Objective: The objective of this selective EBM review is to determine whether or not etanercept is a safe and effective treatment for ankylosing spondylitis (AS). Study Design: Review of three English language randomized control trials published in 2007,
Albert, Robyn M
core  

Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan. [PDF]

J Pharm Policy Pract
Mamiya H, Fukasawa T, Kawakami K.
europepmc   +1 more source

Steroid Refractory and Plasma Exchange Partially Responsive Longitudinally Extensive Transverse Myelitis Due to Tumor Necrosis Factor-Alpha (Etanercept): A Case Report. [PDF]

Clin Pract
Stojsavljevic J, Perez RR, Petcu E, Odenigbo C, Madrid C, Dumic I, Nordstrom CW.   +6 more
europepmc   +1 more source

Predictors of inactive disease and remission in children and young adults with juvenile idiopathic arthritis treated with etanercept. [PDF]

Rheumatology (Oxford)
Chasnyk V, Constantin T, Nikishina I, Bader-Meunier B, Breda L, Doležalová P, Rumba-Rozenfelde I, Wulffraat N, Akikusa J, Avcin T, Burgos-Vargas R, Chaitow J, Carlini L, Tsekouras V, Graham D, Borlenghi C, Vlahos B, Zang C, Ruperto N.   +18 more
europepmc   +1 more source

Tumor necrosis factor-alpha-mediated inflammatory bone loss: Pathogenic mechanisms and therapeutic potential of its inhibitors. [PDF]

Tzu Chi Med J
Lin WY, Pan YJ, Yeh KT, Su KY, Dharini KK, Chen IH, Wu WT, Lin MD, Peng CH.   +8 more
europepmc   +1 more source

Positron Emission Tomography imaging of tumor necrosis factor in lung injury. [PDF]

Ups J Med Sci
Wegrzyniak O, Han H, Eriksson O.
europepmc   +1 more source